Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.
Financial Results:
Sanofi India Ltd reported Revenues for Q2FY25 of ₹524.00 Crores up from ₹491.00 Crore year on year, a rise of 6.72%.
Total Expenses for Q2FY25 of ₹413.00 Crores up from ₹386.00 Crores year on year, a rise of 6.99%.
Consolidated Net Profit of ₹82.00 Crores down 46.05% from ₹152.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹35.74, down 45.99% from ₹66.17 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.